Axonics® receives fda approval further expanding mri labeling

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received fda approval allowing the use of detachable extremity coils for patients undergoing 1.5t and 3.0t mri scans. the fda previously approved 1.5t and 3.0t mri conditional labeling for using head and full-body transmit coils for the implantable components of the axonics r-snm® system.
AXNX Ratings Summary
AXNX Quant Ranking